GSK wanted to review the structure of its batch production record and associated workflows as part of a continuous improvement process. AspenTech was selected for this process due to integration with other solutions, such as Aspen InfoPlus.21® and GSK’s existing plant automation software (DCS). The pilot project was a resounding success, reducing order preparation time by 95% and record review time by over 50%. Read this case study to learn more.

Today’s pharmaceutical manufacturers face increasing pressure to deliver high-quality medicines quickly, efficiently and economically while complying with regulatory requirements and meeting sustainability goals. AspenTech’s Manufacturing Execution Systems (MES) solution digitally guides and records batch procedures in line with the ISPE’s Pharma 4.0 initiative, increasing production quality and reducing cycle time, cost and waste.

In today’s VUCA environment, organizations are turning to digitalization and Industrial AI to develop autonomous and semi-autonomous processes that enable new levels of safety, sustainability and profitability. Learn how Self-Optimizing Plants will enable companies: to empower next-generation workers to focus on the highest-value activities; improve safety and reliability with predictive maintenance to mitigate future events; maximize performance of plant operations by running closer to asset limits and optimizing utilization; and achieve sustainability goals by reducing energy use and avoiding conditions that cause emissions.

How are you keeping up with growing demand? Digitalize batch execution and records with Aspen Production Execution Manager™ to accelerate time-to-market with accuracy while maintaining regulatory compliance.

The pandemic heightened the need for agility and resiliency within the supply chain. Speed to market remains a top business imperative as we move into the next normal for pharma.

Speed to market remains a key driver for the digitalization of long-standing paper-based processes in drug manufacturing. Bottlenecks such as manual execution and review—all associated with bloated documentation—prevent companies from aligning with the FDA’s vision for advanced manufacturing to achieve continuous improvement. Manufacturers like GlaxoSmithKline (GSK) are embracing Pharma 4.0 and paperless technologies to help bring quality medicines to patients more quickly.

Close the gap between planning and execution by improving asset utilization and ensuring efficient and sustainable manufacturing processes.

Close the gap between planning and execution by improving asset utilization and ensuring efficient and sustainable manufacturing processes.

The lighthouse organizations that have paved the way are showing that continuous manufacturing is viable and scalable, lending to greater throughput and consistency in drug quality and ultimately decreasing time-to-market.

Unnecessary downtime can be expensive for pharmaceutical manufacturing operations; unplanned stoppages can delay the delivery of much needed product, potentially causing damage to a company's reputation.